An independent two-stage DCF analysis by a frontier AI model.
Globe Life represents a highly defensive, cash-generative asset. The core operations—marketing life and supplemental health insurance directly to middle-income Americans—are not rapidly growing, but they are exceptionally predictable. The company reliably converts a significant portion of its earnings into free cash flow, currently hovering above $1.1 billion annually.
The valuation proposition is straightforward: Globe Life is a reliable compounding machine. It trades at a relatively modest multiple (under 10x trailing P/E) despite its stability. While it will rarely outpace dynamic growth sectors, its low beta and consistent capital return profile provide a strong foundation. Assuming moderate, single-digit growth aligned with historical norms, the current price appears to offer a margin of safety for conservative investors.
A 3.6% growth rate aligns exactly with the company's recent revenue trajectory. This reflects a mature but highly stable business generating consistent cash flows from long-term insurance policies and direct-marketing channels.
A relatively low 7.5% discount rate is utilized, primarily reflecting Globe Life's extremely low beta (0.455) and the historically non-cyclical, highly predictable nature of its premium revenue streams.
A 2.0% terminal growth rate is assumed, sitting slightly below global GDP expectations. This acknowledges the finite growth potential of its core domestic middle-income market demographic.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 1.0% | $201.91 | $165.20 | $139.78 | $121.15 | $106.89 |
| 1.5% | $227.15 | $181.72 | $151.43 | $129.80 | $113.57 |
| 2.0% | $259.60 | $201.91 | $165.20 | $139.78 | $121.15 |
| 2.5% | $302.87 | $227.15 | $181.72 | $151.43 | $129.80 |
| 3.0% | $363.44 | $259.60 | $201.91 | $165.20 | $139.78 |
■ Undervalued vs current price ■ Overvalued vs current price
The model directly utilizes the recent 3.6% revenue growth figure, projecting that Globe Life will continue its slow but steady expansion within its core insurance demographics, driving a proportional increase in free cash flow.
A 7.5% discount rate was selected. This is largely driven by the company's incredibly low beta (0.455), indicating that its stock price and cash flows are significantly less volatile than the broader market.
Yes, implicitly. As an insurer, Globe Life's profitability is tied to the yield on its investment portfolio. A higher rate environment generally benefits the company long-term, supporting the 3.6% baseline growth assumption.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.